Antimicrobial approvals are not bottlenecked by FDA

Sponsors seeking US Food and Drug Administration (FDA) approval for antimicrobial drugs accessed expedited clinical testing and review programs at least as frequently as those seeking approval of non-antimicrobials, according to a study published Tuesday in The Lancet Infectious Diseases. The median time from investigational new drug (IND) application to drug approval was shorter for antimicrobials than other drugs.